Annual progress report

In 2019, a higher share of Gavi-supported countries than ever before met their co-financing obligations on time, thanks to strong political commitment.

Gavi’s long-term approach to developing healthy markets for critical vaccines has led to greater stability and security, providing countries with the confidence that supplies will be available to meet their demand.

A growing number of countries are transitioning out of Gavi support. Here’s how we help them sustainably finance and manage their vaccine programmes over the long term.

One of the vital components to Gavi’s capital structure is the International Finance Facility for Immunisation (IFFIm). A powerful and award-winning financial tool launched in 2006, IFFIm issues Vaccine Bonds on the capital markets against long-term donor pledges.

The Vaccine Alliance has been working hard in recent years to build greater resilience in supply chains, an effort that is starting to show results.

Building and maintaining demand for immunisation is an integral part of Gavi’s work to increase coverage and equity. Here’s an insight into how we have achieved this.

Over 50% more children were immunised in Gavi countries in 2019 than in 2000, yet 10.6 million children continue to miss out entirely on basic vaccinations. Here’s why reaching these children and setting them on the pathway to full immunisation is our highest priority.

The benefits of immunisation extend beyond preventing childhood deaths. Vaccines are also a vital tool in the fights against cancer, outbreaks and antimicrobial resistance.

After transitioning out of Gavi support in 2017, the Republic of Moldova is mobilising champions and advocates to strengthen vaccine confidence – which is crucial to the success and sustainability of immunisation programmes.

Here’s how Gavi helps lower-income countries get the new vaccines and products they need to address urgent threats to public health – from cholera and COVID-19, to Ebola and pneumonia.